Story by Luis Nhika
ZIMBABWE is intensifying efforts to strengthen the safety, quality and efficacy of medicines as it pursues the highest global standard in pharmaceutical regulation.
The Medicines Control Authority of Zimbabwe (MCAZ) is preparing for a crucial re-benchmarking exercise aimed at securing World Health Organization Maturity Level 4 status, the highest rating for national medicines regulatory systems.
As part of this process, the authority recently hosted a team of experts from the World Health Organization for a Good Manufacturing Practices inspection and audit conducted from April 7 to 10.
The audit forms part of preparations for the WHO Global Benchmarking Tool assessment, which evaluates the performance, competence and effectiveness of a country’s medicines regulatory framework.
MCAZ Director General Mr Richard Tendayi Rukwata said the exercise is a critical step towards achieving regulatory excellence.
“The exercise provides an opportunity to identify strengths and areas for further improvement as we continue our journey towards regulatory excellence. This engagement reflects our commitment to ensuring that medicines and medical products in Zimbabwe meet the highest standards,” he said.
If successful, Zimbabwe would become the first country in Africa to attain WHO Maturity Level 4 status, placing its regulatory system among the most advanced globally.
Experts say such an achievement would significantly enhance public health outcomes by guaranteeing safer, high-quality medicines for Zimbabweans.
Beyond health benefits, the milestone is also expected to boost international confidence in Zimbabwe’s pharmaceutical sector, attracting investment, expanding export opportunities and positioning the country as a regional leader in medicines regulation.
The move underscores Zimbabwe’s broader commitment to strengthening healthcare systems and aligning with international best practice in pharmaceutical oversight.
